Overview

A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
A phase 1, dose escalation study of evorpacept (ALX148) in patients with advanced solid tumors and lymphoma
Phase:
Phase 1
Details
Lead Sponsor:
Alexo Therapeutics, Inc.
ALX Oncology Inc.
Treatments:
Antibodies, Monoclonal
Paclitaxel
Pembrolizumab
Ramucirumab
Rituximab
Trastuzumab